Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

As part of its commitment to developing better medicines for Duchenne Muscular Dystrophy (DMD), WAVE has extended its ongoing research collaboration with the University of Oxford to advance stereopure nucleic acid therapies for DMD across exons.

microRNA array identifying extracellular microRNAs elevated in mdx mouse serum and normalised following peptide-conjugated oligonucleotide therapy

 microRNA array identifying extracellular microRNAs elevated in mdx mouse serum and normalised following peptide-conjugated oligonucleotide therapy

Through the collaboration, renowned researcher Matthew Wood and his team will continue to work with WAVE to use the company’s proprietary platform to enhance oligonucleotide approaches, including exon-skipping, to address the rare genetic muscle disease.
 
“The data we have seen to date using WAVE’s novel approach to exon-skipping in DMD is very promising. I believe that academia and industry, working together, may be on the verge of a veritable medical revolution where we can potentially effectively and durably treat genetically based diseases such as DMD,” said Professor Wood.

“Collaborations between academia and industry are critical now more than ever in order to collectively harness the latest scientific advancements to rapidly progress therapies for patients. We look forward to expanding our collaboration with the WAVE team and advancing the potential and benefits of stereopure oligonucleotide approaches for DMD.”

Read more

Similar stories

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

Drug could help diabetic hearts recover after a heart attack

New research led by Associate Professor Lisa Heather has found that a drug known as molidustat, currently in clinical trials for another condition, could reduce risk of heart failure after heart attacks.

Blood bank storage can reduce ability of transfusions to treat anaemia

New research from the Swietach Group in collaboration with NHS Blood and Transplant has demonstrated that the process of storing blood in blood banks can negatively impact the function of red blood cells and consequently may reduce the effectiveness of blood transfusions, a treatment commonly used to combat anaemia.

Overlapping second messengers increase dynamic control of physiological responses

New research from the Parekh and Zaccolo groups reveals that a prototypical anchoring protein, known to be responsible for regulating several important physiological processes, also orchestrates the formation of two important universal second messengers.